Search PubMed⌕ Search

Biomedical subjects

E Posner

Publications and source records attributed to E Posner.

At least 19 recordsLinked to original sources
PubMed2000

Six-year follow-up of children with intrauterine growth retardation: long-term, prospective study.

This prospective study was designed to characterize the neurodevelopmental and cognitive difficulties specific to children with intrauterine growth retardation and to detect early clinical predictors of these difficulties. Eighty-one children with intrauterine growth retardation were monitored up to 6 to 7 years of age using biometric parameters, perinatal risk questionnaires, and detailed neurodevelopmental and cognitive assessments. Forty-one children served as age-matched, appropriate for gestational age controls. A significant difference in growth parameters (P < .001), neurodevelopmental score (P < .05), and IQ (P < .05) was found between the children with intrauterine growth retardation and controls. A specific profile of difficulties in coordination, lateralization, spatial and graphomotor skills, and abundance of associated movements is typical of the children with intrauterine growth retardation and hints at possible later learning disabilities. The clinical parameters best predicting neurodevelopmental outcome were the neonatal risk score (P < .05) and the weight and height at 6 years of age (P < .05). The children with intrauterine growth retardation with neonatal complications had lower neurodevelopmental scores than the controls but no difference in IQ. Intrauterine growth retardation children diagnosed prenatally had the same neurodevelopmental and IQ scores as those diagnosed at birth, probably due to the careful perinatal and obstetric care provided. Children with intrauterine growth retardation demonstrate a specific profile of neurodevelopmental disabilities at preschool age. Early diagnosis and intervention could probably reduce these difficulties to a minimum.

Child↗
PubMed1975

New bronchodilator aerosol, salmefamol, in asthma.

Twenty-five asthmatics were tested with salmefamol aerosol (200 mug q.d.s.) for a period of 3 months. The ventilatory capacity before and after adrenaline was measured weekly and symptoms were assessed daily using a scoring system over a period of 9 months. The results during the 3 months' treatment with salmefamol were compared with the preceding and succeeding 3-month-periods when patients were receiving either salbutamol aerosol or orciprenaline aerosol. Statistically significant improvements were seen in ventilatory capacity before adrenaline inhalation and in symptom scores while on salmefamol. Ventilatory capacity after adrenaline inhalation remained unchanged throughout the study: thus there was no evidence of tachyphylaxis. A significantly greater number of patients preferred the new drug. Four patients developed slight muscle tremor in the first few days of salmefamol therapy, but there were no changes in haematological or biochemical values after 3 months' therapy. Thus, salmefamol seems to have marked efficacy with low toxicity and is generally well tolerated.

Adolescent↗
PubMed1970

Pleural effusion and fibrosis during treatment with methysergide.

Two patients being treated for migraine with methysergide developed extensive pleural fibrosis, and in addition one of them had bilateral pleural effusions, After treatment was stopped these complications, which are thought to have been due to the drug, cleared in the next few months.

Adult↗